Skip to main content

EDITORIAL article

Front. Endocrinol., 28 March 2023
Sec. Molecular and Structural Endocrinology
This article is part of the Research Topic Functional Epigenetic Regulation in Metabolic Diseases View all 9 articles

Editorial: Functional epigenetic regulation in metabolic diseases

  • 1Medical School, Nanjing University, Nanjing, China
  • 2Department of Biosciences and Nutrition, Karolinska Institutet (KI), Stockholm, Sweden
  • 3Jiangsu Innovation Institute for Biomedicine, Nanjing, China
  • 4Institute of Epigenetics and Epigenomics, Yangzhou University, Yangzhou, China

Human metabolism is delicately coordinated by transcription networks and disturbance of such process is closely linked to a range of diseases, including metabolic disorders, autoimmune diseases, and cancer (13). Transcriptional alterations are tightly controlled in the chromatin level through epigenetic mechanisms such as histone modification and DNA methylation (4). Epigenetic remodeling is essential not only for the fine-tuned transcriptional waves during developmental process but also play crucial roles to define disease-related transcription signatures. Investigation into these events, including the chromatin modification process and the underlying regulatory mechanisms involving transcription factors and coregulators, will provide valuable insights for therapeutic interventions (5).

DNA methylation is one of the most extensively studied epigenetic marks, and its functional role is well established (6). For instance, using a methylated DNA immunoprecipitation chip (MeDIP-chip) technique in cardiovascular disease cohort, Hu et al. found that changes in DNA methylation levels were associated with several VEGFR signaling pathway genes (VEGFB, PLGF, FATP3, F2R, FATP4), potentiating their roles as disease biomarkers. Additionally, the author also found calcium signaling pathway genes (PLCB1, CAMK1D, DRD5) were anomalous methylated in participants.

DNA point mutations can occur frequently due to genetic and environmental factors, some of which are significantly associated with diseases such as metabolic disorders (2). Hou et al. reported that frameshift mutations in KASH5 can lead to infertility in both sexes, by disrupting the interaction of KASH5 and SUN1. As a result, the reproductive development is halted. The discovery could potentially serve as a genetic foundation for the molecular diagnosis of conditions such as azoospermia (NOA), diminished ovarian reserve (DOR), and recurring miscarriages. Similarly, missense mutations (N162D) in exon 3 of FGF23 are closely associated with hyperphosphatemia familial neoplastic calcinosis (HFTC) by hindering the glycosylation of its protein, as introduced by Zuo et al. The authors found that the mutated FGF23 protein has defective glycosylation levels and protein stability. By utilizing resources from online databases, Wang et al. found that mutations in the PRKAR1A gene are linked to hyperthyroidism, with high PRKAR1A prevalence significantly associated with hyperthyroidism. In another bladder cancer cohort, Qu et al. found that variations (rs17110453, rs1934951, rs1934953, and rs2275620) in the CYP2C8 gene are closely related to bladder cancer. These findings suggest that these genetic variations could potentially be used as a novel biomarker for identifying and preventing bladder cancer in population. These examples demonstrate how functional mutations can have profound effects on protein function and disease outcomes.

Transcription factor inactivation can contribute to metabolic disorders and diseases, as demonstrated by recent studies (7). Specifically, the TBX19 gene is critical for brain cognition (8). The mutation (Glu280Asp) in TBX19 is associated with isolated ACTH deficiency (IAD) and cognitive impairment reported by Charnay et al. Additionally, the study found that mutations in the TBX19 gene can occur at multiple sites, with multiple pathological effects. PPARG2 plays a crucial role in fatty acid metabolism and has a strong association with obesity (9, 10). In a biochemical study, Zhang et al. found that niacin can regulate β-cell lipotoxicity through its effects on GPR109A and PPARG2. Incretin drugs have been found to alleviate these effects, although the underlying mechanism is not yet fully understood. One possibility is that niacin modulates the expression of GPR109A and PPARG2 by modifying the affinity of specific transcription factors. According to a clinical study from Yang et al., a decrease in the GRIM-19 gene expression is correlated with autophagy-related proteins such as BECLIN1, LC3BII/I and BNIP3, which have been linked to recurrent spontaneous abortion (RSA). The underlying mechanism behind this association is believed to be attributed to the activation of immune and inflammation-related pathways in THP-1 macrophages. The examples presented demonstrate the importance of transcription factors in the pathogenesis of diseases and underscore the need for further research on their role in disease development. Therefore, further research on transcription factors and their role in disease development is essential for advancing medical knowledge and developing new therapeutic interventions.

While there have been significant efforts in the field of functional epigenetics, uncovering their roles in diseases remains a challenge. More work is required to map tissue- and disease-relevant epigenetic alterations in the patients and to investigate the regulatory mechanisms underlying such epigenetic signatures. This information will be crucial in developing effective treatments for metabolic diseases, tumors, and innate immune diseases.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

Lilly Young Investigator Award 97081 (to ZH). Study on the Epigenetic Mechanism of Silencing of Tumor Suppressor Genes by Antisense RNAs (Natural Science Foundation of China, No.81372237, to HC).

Acknowledgments

We would like to thank all the co-authors and especially the editors and reviewers for their time and dedication to this Research Topic.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Kagohara LT, Stein-O’Brien GL, Kelley D, Flam E, Wick HC, Danilova LV, et al. Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Brief Funct Genomics (2018) 17:49–63. doi: 10.1093/bfgp/elx018

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Barroso I, McCarthy MI. The genetic basis of metabolic disease. Cell (2019) 177:146–61. doi: 10.1016/j.cell.2019.02.024

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Mazzone R, Zwergel C, Artico M, Taurone S, Ralli M, Greco A, et al. The emerging role of epigenetics in human autoimmune disorders. Clin Epigenet (2019) 11:34. doi: 10.1186/s13148-019-0632-2

CrossRef Full Text | Google Scholar

4. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation (2011) 123:2145–56. doi: 10.1161/CIRCULATIONAHA.110.956839

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Wang K, Liu H, Hu Q, Wang L, Liu J, Zheng Z, et al. Epigenetic regulation of aging: implications for interventions of aging and diseases. Signal Transduct Target Ther (2022) 7:374. doi: 10.1038/s41392-022-01211-8

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Takahashi Y, Morales Valencia M, Yu Y, Ouchi Y, Takahashi K, Shokhirev MN, et al. Transgenerational inheritance of acquired epigenetic signatures at CpG islands in mice. Cell (2023) 186:715–31.e719. doi: 10.1016/j.cell.2022.12.047

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Kandula V, Kosuru R, Li H, Yan D, Zhu Q, Lian Q, et al. Forkhead box transcription factor 1: role in the pathogenesis of diabetic cardiomyopathy. Cardiovasc Diabetol (2016) 15:44. doi: 10.1186/s12933-016-0361-1

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Peng C, Sun G, Tang Z, Hou X. Congenital isolated ACTH deficiency caused by TBX19 gene mutation: A family report. Front Pediatr (2019) 7:546. doi: 10.3389/fped.2019.00546

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue treg cells. Nature (2012) 486:549–53. doi: 10.1038/nature11132

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Saraf N, Sharma PK, Mondal SC, Garg VK, Singh AK. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. J Pharm Pharmacol (2012) 64:161–71. doi: 10.1111/j.2042-7158.2011.01366.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: epigenetics, gene dysfunction, SNPs, DNA methylation, transcription factor, diseases

Citation: Huang Z and Cui H (2023) Editorial: Functional epigenetic regulation in metabolic diseases. Front. Endocrinol. 14:1190693. doi: 10.3389/fendo.2023.1190693

Received: 21 March 2023; Accepted: 21 March 2023;
Published: 28 March 2023.

Edited and Reviewed by:

Pierre De Meyts, Université catholique de Louvain, Belgium

Copyright © 2023 Huang and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhiqiang Huang, zhiqiang.huang@ki.se

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.